Topics Topics Help/Instructions Help Edit Profile Profile Member List Register Paatha Gnyapakaalu - Archives from Old DB  
Search New Posts 1 | 2 | 8 Hours Search New Posts 1 | 3 | 7 Days Search Search Tree View Tree View Latest tweets Live Tweets   Hide Images

Rate this post by selecting a number. 1 is the worst and 5 is the best.

    (Worst)    1    2    3    4    5     (Best)

Author Message
Top of pagePrevious messageNext messageBottom of page Link to this message

Entrepreneur
Kurra Bewarse
Username: Entrepreneur

Post Number: 3374
Registered: 05-2011
Posted From: 65.35.45.47

Rating: N/A
Votes: 0

Posted on Thursday, March 04, 2021 - 7:12 pm:   

QTRX is a life sciences co that has developed ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Quanterix's platforms are based on its proprietary digital "Simoa" detection technology. Quanterix's Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Simoa is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. QTRX is also a pandemic play as it was able to quickly pivot to producing COVID-19 testing capabilities. Its advances in ultra-sensitive proteomics testing enable top researchers to tackle important COVID challenges and accelerate its Neurology tools strategy with vital new additions to its assay menu supporting both Alzheimer's and COVID-19 research and diagnostics. The stock has been rallying over the past week since QTRX provided bullish revenue guidance for Q4 that surprised a lot of people. QTRX was also recently awarded an $18.2 mln contract with the NIH to accelerate the development of a SARS-CoV-2 antigen test. On a final note, while QTRX's technology looks promising, we'd be cautious about chasing it up here given its big move. But it's worth keeping on the radar for a pullback

Topics | Last Hour | Last Day | Last Week | Tree View | Search | Help/Instructions | Program Credits Administration